Navigation Links
Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)
Date:5/20/2013

s.

"I am very encouraged by the results of this 20 subject open-label study.  The treatment is safe, well received by children and adolescents with ADHD, and has suggested potential as a non-medication ADHD therapy. The results of the study warrant moving forward with a larger double-blind Phase II clinical trial.  I would like to thank members of my team for their hard work and NeuroSigma for supporting this study," said Dr. McGough.

"PET imaging studies we had conducted in humans showed immediate effects of eTNS on activity in centers in the brain associated with attention," said Ian Cook , M.D., Director of the UCLA Depression Research & Clinic Program and Chief Medical Advisor to NeuroSigma. "These observations served as an initial road map for a likely mechanism of action for eTNS on ADHD, and we are very encouraged that the results of Dr. McGough's study showed robust clinical effects.  As has been the case with eTNS trials to date in epilepsy, depression and PTSD, the participants in this study told us that the eTNS device was easy to use at home and there were no significant adverse events related to use of the system.

"These results not only demonstrate that the eTNS system has the potential to provide parents with a non-drug option to manage their children's ADHD and relieve them of worries about their child's use of stimulants, but also provide encouraging data for pediatricians, child psychologists and child psychiatrists who worry about drug side effects and who have concerns about how stimulant drugs may be abused outside the clinical setting," said Dr. Cook.

"We would like to applaud the hard work of Dr. McGough and his clinical team at UCLA for this important work and look forward to continuing to support their activities in the future," added Lodwrick Cook, Chairman of NeuroSigma. 

"ADHD is a very high priority indication for NeuroSigma. We are committed to m
'/>"/>

SOURCE NeuroSigma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Positive Clinical Study Results for BSPs HyperQ Technology
3. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
4. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
5. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
6. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
7. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
8. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
9. Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
10. Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association
11. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... (PRWEB) July 12, 2014 ... various reagents used in the life science ... the life science reagents market towards remarkable ... manufacturers and providers of life science reagents. ... Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global ...
(Date:7/11/2014)... 11, 2014 , Not for release, ... or from any jurisdiction where to do so would constitute ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ...  Shire confirms it has held a meeting with representatives of ... without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... July 11, 2014 BCC Research ( ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , ... technology reached nearly $140 billion in 2013. This is ... a five-year compound annual growth rate (CAGR) of 28.6%. ... of interesting and exciting possibilities within the broader PCR ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... that's how we're acting. The grand majesty of the IT ... world. Yeah, we send the occasional skirmish over into the ... business" is, but our maps of the world mostly contain ... technology. , ,Then there's that blue ocean of business process. ...
... to keep down costs by allowing people to make initial ... according to The Times of Monroe , ,A ... the county could save $8,000 to $13,000 per year by ... would cost $35,000. , ,The state will provide about $22,000 ...
... Aidmatrix , a non-profit in Texas that helps match ... named former Wisconsin governor Scott McCallum its president and ... a software donation from I2 Technologies , a ... methods of getting donations and excess supplies to humanitarian ...
Cached Biology Technology:Information technology past the end of the Earth 2Information technology past the end of the Earth 3Online aid group taps former Wisconsin governor McCallum 2Online aid group taps former Wisconsin governor McCallum 3
(Date:7/11/2014)... Research awarded Michael F. Holick, PhD, MD, of Boston ... V. Avioli Award. Holick, a professor of medicine, physiology ... the understanding of vitamin D and its role in ... of the American Society for Bone and Mineral Research ... research. It is named for ASBMR,s first president and ...
(Date:7/11/2014)... 10, 2014---A team of researchers from The Chinese University ... a gene of wild soybean linked to salt tolerance, ... in saline soil. This study published online in ... novel genomic information for crop improvement. , Soybean is ... and human selection, cultivated soybeans have less genetic diversities ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... 12, 2009 An international conference that will explore ... University May 25-29. It is being organized to coincide ... On the Origin of Species, (and the 200th anniversaryspecifically, ... Einstein of biology," says Ralph Pudritz, director of McMaster,s ...
... CITYUnraveling the genetics of social behavior and cognitive abilities, ... Institute for Biological Studies have traced the role of ... known as Williams Syndrome. Their results, published ... American Journal of Medical Genetics , suggest that ...
... -- The rangelands of Iran have one of the world,s ... technological developments and knowledge of the soil that has produced ... an increasing population of humans and livestock in the region ... suggests that the soil is rapidly degrading. With the land ...
Cached Biology News:2 genes influence social behavior, visual-spatial performance in people with Williams syndrome 22 genes influence social behavior, visual-spatial performance in people with Williams syndrome 3Preventing rangeland erosion: Developing better management practices in Iran 2